TY  - JOUR
T1  - Searches for heavy \({ZZ}\) and \({ZW}\) resonances in the \({llqq}\) and \({vvqq}\) final states in \({pp}\) collisions at root s=13 TeV with the ATLAS detector
JF  - Journal of High Energy Physics
N2  - This paper reports searches for heavy resonances decaying into ZZ or ZW using data from proton-proton collisions at a centre-of-mass energy of root s - 13 TeV. The data, corresponding to an integrated luminosity of 36.1 fb(-1), were recorded with the ATLAS detector in 2015 and 2016 at the Large Hadron Collider. The searches are performed in final states in which one Z boson decays into either a pair of light charged leptons (electrons and muons) or a pair of neutrinos, and the associated W boson or the other Z boson decays hadronically. No evidence of the production of heavy resonances is observed. Upper bounds on the production cross sections of heavy resonances times their decay branching ratios to ZZ or ZW are derived in the mass range 300-5000 GeV within the context of Standard Model extensions with additional Higgs bosons, a heavy vector triplet or warped extra dimensions. Production through gluon-gluon fusion, Drell-Yan or vector-boson fusion are considered, depending on the assumed model.
KW  - Beyond Standard Model
KW  - Hadron-Hadron scattering (experiments)
KW  - Boson
KW  - Distributions
KW  - Combination
KW  - Hierarchy
KW  - Mass
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-225951
VL  - 9
ER  - 
TY  - JOUR
A1  - Kreissl, Michael C.
A1  - Hänscheid, Heribert
A1  - Löhr, Mario
A1  - Verburg, Frederik A.
A1  - Schiller, Markus
A1  - Lassmann, Michael
A1  - Reiners, Christoph
A1  - Samnick, Samuel S.
A1  - Buck, Andreas K.
A1  - Flentje, Michael
A1  - Sweeney, Reinhart A.
T1  - Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma
N2  - Background: External beam radiotherapy (EBRT) is the treatment of choice for irresectable meningioma. Due to the strong expression of somatostatin receptors, peptide receptor radionuclide therapy (PRRT) has been used in advanced cases. We assessed the feasibility and tolerability of a combination of both treatment modalities in advanced symptomatic meningioma. Methods: 10 patients with irresectable meningioma were treated with PRRT (177Lu-DOTA0,Tyr3 octreotate or - DOTA0,Tyr3 octreotide) followed by external beam radiotherapy (EBRT). EBRT performed after PRRT was continued over 5–6 weeks in IMRT technique (median dose: 53.0 Gy). All patients were assessed morphologically and by positron emission tomography (PET) before therapy and were restaged after 3–6 months. Side effects were evaluated according to CTCAE 4.0. Results: Median tumor dose achieved by PRRT was 7.2 Gy. During PRRT and EBRT, no side effects>CTCAE grade 2 were noted. All patients reported stabilization or improvement of tumor-associated symptoms, no morphologic tumor progression was observed in MR-imaging (median follow-up: 13.4 months). The median pre-therapeutic SUVmax in the meningiomas was 14.2 (range: 4.3–68.7). All patients with a second PET after combined PRRT + EBRT showed an increase in SUVmax (median: 37%; range: 15%–46%) to a median value of 23.7 (range: 8.0–119.0; 7 patients) while PET-estimated volume generally decreased to 81 ± 21% of the initial volume. Conclusions: The combination of PRRT and EBRT is feasible and well tolerated. This approach represents an attractive strategy for the treatment of recurring or progressive symptomatic meningioma, which should be further evaluated.
KW  - Medizin
KW  - PRRT
KW  - Peptide receptor radionuclide therapy
KW  - Meningioma
KW  - Radiotherapy
KW  - EBRT
KW  - Combination
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-75540
ER  -